RARE (Ultragenyx Pharmaceutical) Net Income (Continuing Operations): $-586.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RARE Ultragenyx Pharmaceutical Inc RARE
64 GF Score
Price $14.30
GF Value $45.38
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical Net Income (Continuing Operations)?

Ultragenyx Pharmaceutical RARE -0.56% 64 Net Income (Continuing Operations) is $-586.0 Mil as of Jun. 2026. GuruFocus rates RARE with a GF Score™ of 64/100 and a GF Value™ of $45.38 (Possible Value Trap). The stock has 5 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Ultragenyx Pharmaceutical's Net Income (Continuing Operations) for the three months ended in Jun. 2026 was $-92.0 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was $-586.0 Mil.

Ultragenyx Pharmaceutical  (NAS:RARE) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Ultragenyx Pharmaceutical Net Income (Continuing Operations) Related Terms

Ultragenyx Pharmaceutical Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Ultragenyx Pharmaceutical's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical Net Income (Continuing Operations) Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -454.03 -707.42 -607.00 -569.00 -575.00

Ultragenyx Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -115.00 -180.41 -128.56 -185.00 -92.00
RARE
64GF Score
Ultragenyx Pharmaceutical Inc RARE
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ultragenyx Pharmaceutical Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-586.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-586.0 Mil mean?
Ultragenyx Pharmaceutical (RARE) has a Net Income (Continuing Operations) of $-586.0 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Ultragenyx Pharmaceutical and its competitors.
Is Ultragenyx Pharmaceutical's Net Income (Continuing Operations) too high?
Ultragenyx Pharmaceutical's current Net Income (Continuing Operations) is $-586.0 Mil. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Net Income (Continuing Operations) compare to PGEN and PHVS?
Ultragenyx Pharmaceutical's Net Income (Continuing Operations) of $-586.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Ultragenyx Pharmaceutical and its competitors. Ultragenyx Pharmaceutical's current Net Income (Continuing Operations) is $-586.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical (RARE) is currently considered Possible Value Trap. The stock's GF Value™ is $45.38, compared to a current price of $14.30 — trading 68.5% below its estimated fair value. The current Net Income (Continuing Operations) is $-586.0 Mil. Ultragenyx Pharmaceutical's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (RARE), the current Net Income (Continuing Operations) is $-586.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ultragenyx Pharmaceutical (RARE) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of $14.30 is trading 68.5% below its estimated GF Value™ of $45.38. GuruFocus considers Ultragenyx Pharmaceutical to be Possible Value Trap.

Key valuation signals for RARE:

  • Net Income (Continuing Operations): $-586.0 Mil
  • GF Value™: $45.38 vs. price of $14.30 (68.5% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ultragenyx Pharmaceutical Business Description

Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
64GF Score

Get the complete analysis for RARE

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.30
Price
$45.38
GF Value